Zymeworks is pleased to announce the acceptance of an abstract for poster presentation at the European Society for Medical Oncology World Congress on Gastrointestinal Cancers (ESMO GI) taking place in Barcelona, Spain from June 29 to July 2, 2022. The Trials in Progress poster will review Zymeworks’ global Phase 3 study, HERIZON-GEA-01 (NCT05152147), which will investigate zanidatamab in combination with chemotherapy plus or minus tislelizumab for first-line treatment of locally advanced, unresectable, or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA).
Title: HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)
Author: Josep Tabernero
Poster ID: P-26
Category: Clinical Gastric Cancer
The presentation will be available to conference registrants on the conference website as well as to the general public at www.zymeworks.com/publications at the time of presentation at the conference.